# MSCs for Prevention of MI-induced HF

Study · id `cardio:ct-nct05043610` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05043610](<https://clinicaltrials.gov/study/NCT05043610>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05043610

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

## Technical summary

Registry record NCT05043610. Randomized; single masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2024-11-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 420 participants (enrolled count; ClinicalTrials.gov record NCT05043610, source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)
- Started: 2021-09-15 (actual) (ClinicalTrials.gov record NCT05043610, source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)
- Primary completion: 2024-11-01 (actual) (ClinicalTrials.gov record NCT05043610, source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)
- Completion: 2024-11-01 (actual) (ClinicalTrials.gov record NCT05043610, source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT05043610, source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05043610-2024-11-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: MSCs for Prevention of MI-induced HF
- Acronym: PREVENT-TAHA8
- Condition: Myocardial Infarction, Acute
- Condition: Myocardial Infarction First
- Condition: Myocardial Infarction, Anterior Wall
- Condition: Cardiac Remodeling, Ventricular
- Condition: STEMI
- Condition: Regenerative Medicine
- Condition: Heart Failure
- Intervention (Biological): Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)
- Intervention (Other): Conventional Treatment
- Lead sponsor: Shiraz University of Medical Sciences
- Lead sponsor class: OTHER
- Collaborator: National Institute for Medical Research and Development
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Shiraz University of Medical Sciences (`cardio:org-shiraz-university-of-medical-sciences`)

## Provenance

Content hash: 02a37aedac20b83efc46bbffb445d211abfe8e99b25d19087d6e1738ec178711
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
